MedTrace Logo

Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

NCT01413048 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2011-08-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antihypertensive effect of AGSCT101 tablet in patient with stage 1 to 2 essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Carvedilol 25mg

Tablet, q.d.

DRUG

AGSCT101 12.5mg

Tablet, q.d.

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Ki-Bae Seung, Professor · The Catholic University of Korea-St. Mary's Hospital

  • Hun-Sik Park, Professor · Kyungpook National University Hospital

  • Chang-Gyu Park, Professor · Korea University Guro Hospital

  • Moo-Yong Rhee, Professor · Dongguk University Medical Center

  • Dong-Ju Choi, Professor · Seoul National University Bundang Hospital

  • Seung-Jea Tahk, Professor · Ajou University School of Medicine

  • Jung-Han Yoon, Professor · Wonju Christian Hospital

  • Sung-Ha Park, Professor · Severance Hospital

  • Myung-Ho Jeong, Professor · Chonnam National University Hospital

  • Sang-Wook Kim, Professor · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-03-31
Completion
2012-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413048 on ClinicalTrials.gov